HU230416B1 - 6-Helyzetben szubsztituált indolinonok, előállításuk és alkalmazásuk gyógyszerként - Google Patents

6-Helyzetben szubsztituált indolinonok, előállításuk és alkalmazásuk gyógyszerként Download PDF

Info

Publication number
HU230416B1
HU230416B1 HU0204587A HUP0204587A HU230416B1 HU 230416 B1 HU230416 B1 HU 230416B1 HU 0204587 A HU0204587 A HU 0204587A HU P0204587 A HUP0204587 A HU P0204587A HU 230416 B1 HU230416 B1 HU 230416B1
Authority
HU
Hungary
Prior art keywords
methyl
aniline
ethyl
amino
alkyl
Prior art date
Application number
HU0204587A
Other languages
English (en)
Hungarian (hu)
Inventor
Armin Heckel
Gerald Jürgen ROTH
Rainer Walter
Jacobus Van Meel
Norbert Redemann
Ulrike Tontsch-Grunt
Walter Spevak
Frank Hilberg
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU230416(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19949208A external-priority patent/DE19949208A1/de
Priority claimed from DE2000142696 external-priority patent/DE10042696A1/de
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of HUP0204587A2 publication Critical patent/HUP0204587A2/hu
Publication of HUP0204587A3 publication Critical patent/HUP0204587A3/hu
Priority to HUS1600022C priority Critical patent/HUS1600022I1/hu
Publication of HU230416B1 publication Critical patent/HU230416B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0204587A 1999-10-13 2000-10-09 6-Helyzetben szubsztituált indolinonok, előállításuk és alkalmazásuk gyógyszerként HU230416B1 (hu)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HUS1600022C HUS1600022I1 (hu) 1999-10-13 2016-05-13 6-Helyzetben szubsztituált indolinonok, elõállításuk és alkalmazásuk gyógyszerként

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19949208.5 1999-10-13
DE19949208A DE19949208A1 (de) 1999-10-13 1999-10-13 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE2000142696 DE10042696A1 (de) 2000-08-31 2000-08-31 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10042696.4 2000-08-31
PCT/EP2000/009867 WO2001027081A1 (de) 1999-10-13 2000-10-09 In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
HUP0204587A2 HUP0204587A2 (en) 2003-05-28
HUP0204587A3 HUP0204587A3 (en) 2004-07-28
HU230416B1 true HU230416B1 (hu) 2016-05-30

Family

ID=26006858

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0204587A HU230416B1 (hu) 1999-10-13 2000-10-09 6-Helyzetben szubsztituált indolinonok, előállításuk és alkalmazásuk gyógyszerként
HUS1600022C HUS1600022I1 (hu) 1999-10-13 2016-05-13 6-Helyzetben szubsztituált indolinonok, elõállításuk és alkalmazásuk gyógyszerként

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1600022C HUS1600022I1 (hu) 1999-10-13 2016-05-13 6-Helyzetben szubsztituált indolinonok, elõállításuk és alkalmazásuk gyógyszerként

Country Status (42)

Country Link
EP (2) EP1224170B9 (US07585860-20090908-C00150.png)
JP (2) JP4021664B2 (US07585860-20090908-C00150.png)
KR (2) KR100857734B1 (US07585860-20090908-C00150.png)
CN (1) CN100455568C (US07585860-20090908-C00150.png)
AR (1) AR026036A1 (US07585860-20090908-C00150.png)
AT (1) ATE439342T1 (US07585860-20090908-C00150.png)
AU (1) AU781939B2 (US07585860-20090908-C00150.png)
BE (1) BE2015C018I2 (US07585860-20090908-C00150.png)
BG (1) BG65983B1 (US07585860-20090908-C00150.png)
BR (1) BRPI0014735B8 (US07585860-20090908-C00150.png)
CA (1) CA2387013C (US07585860-20090908-C00150.png)
CO (1) CO5261488A1 (US07585860-20090908-C00150.png)
CY (2) CY1110067T1 (US07585860-20090908-C00150.png)
CZ (1) CZ301073B6 (US07585860-20090908-C00150.png)
DE (1) DE50015711D1 (US07585860-20090908-C00150.png)
DK (1) DK1224170T5 (US07585860-20090908-C00150.png)
EA (1) EA006080B1 (US07585860-20090908-C00150.png)
EE (1) EE05427B1 (US07585860-20090908-C00150.png)
EG (1) EG25931A (US07585860-20090908-C00150.png)
ES (1) ES2331459T3 (US07585860-20090908-C00150.png)
FR (1) FR15C0024I2 (US07585860-20090908-C00150.png)
HK (1) HK1052505B (US07585860-20090908-C00150.png)
HR (1) HRP20020306B1 (US07585860-20090908-C00150.png)
HU (2) HU230416B1 (US07585860-20090908-C00150.png)
IL (2) IL148756A0 (US07585860-20090908-C00150.png)
LU (1) LU92681I2 (US07585860-20090908-C00150.png)
ME (1) MEP45408A (US07585860-20090908-C00150.png)
MX (1) MXPA02002799A (US07585860-20090908-C00150.png)
MY (1) MY127956A (US07585860-20090908-C00150.png)
NL (1) NL300725I2 (US07585860-20090908-C00150.png)
NO (3) NO322746B1 (US07585860-20090908-C00150.png)
NZ (1) NZ518489A (US07585860-20090908-C00150.png)
PE (1) PE20010671A1 (US07585860-20090908-C00150.png)
PL (1) PL207445B1 (US07585860-20090908-C00150.png)
PT (1) PT1224170E (US07585860-20090908-C00150.png)
RS (1) RS51013B (US07585860-20090908-C00150.png)
SA (1) SA01210704B1 (US07585860-20090908-C00150.png)
SI (1) SI1224170T1 (US07585860-20090908-C00150.png)
SK (1) SK287312B6 (US07585860-20090908-C00150.png)
TW (1) TWI268922B (US07585860-20090908-C00150.png)
UA (1) UA75054C2 (US07585860-20090908-C00150.png)
WO (1) WO2001027081A1 (US07585860-20090908-C00150.png)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2282299T3 (es) 2000-10-20 2007-10-16 EISAI R&D MANAGEMENT CO., LTD. Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1471907B1 (en) * 2001-06-29 2008-07-16 AB Science Use of c-kit inhibitors for treating autoimmune diseases
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
JP2005500041A (ja) 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のc−kit阻害剤
PT1401413E (pt) 2001-06-29 2007-02-28 Ab Science Uso de inibidores da tirosina cinase para tratar doenças alérgicas
ATE330608T1 (de) 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
ATE343415T1 (de) 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
CA2461812C (en) * 2001-09-27 2011-09-20 Allergan, Inc. 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
IL162203A0 (en) 2001-12-27 2005-11-20 Theravance Inc Indolinone derivatives useful as protein inase inhibitors
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
ITBO20020198A1 (it) * 2002-04-12 2003-10-13 Univ Bologna Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
KR101445892B1 (ko) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
US20100184747A1 (en) * 2007-06-12 2010-07-22 Boehringer Ingelheim International Gmbh Indoline derivatives and their use in treating disease-states such as cancer
WO2008155421A2 (en) 2007-06-21 2008-12-24 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
NZ585799A (en) * 2007-12-03 2012-04-27 Boehringer Ingelheim Int Process for the manufacture of an indolinone derivative in particular 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
UY31506A1 (es) * 2007-12-03 2009-08-03 Derivados de indolinona y procedimiento para su preparacion
RS57035B1 (sr) 2008-06-06 2018-05-31 Boehringer Ingelheim Int Farmaceutska kombinacija
TW201011002A (en) 2008-07-29 2010-03-16 Boehringer Ingelheim Int New compounds
JP2012515184A (ja) 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大腸がんの治療方法
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP3604307A1 (en) 2012-01-26 2020-02-05 Angion Biomedica Corp. Anti-fibrotic compounds and uses thereof
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
JP6207625B2 (ja) * 2012-12-06 2017-10-04 山東亨利醫藥科技有限責任公司 チロシンキナーゼ阻害剤としてのインドリノン誘導体
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
AU2014266223B2 (en) 2013-05-14 2020-06-25 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
CN104262232B (zh) * 2014-09-09 2016-05-04 苏州明锐医药科技有限公司 尼泰达尼的制备方法
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (zh) * 2015-06-05 2017-03-08 北京康立生医药技术开发有限公司 一锅法制备尼达尼布的合成方法
WO2016200688A1 (en) 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CZ308695B6 (cs) 2015-07-29 2021-03-03 Zentiva, K.S. Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu)
CN106467500A (zh) * 2015-08-14 2017-03-01 廊坊百瑞化工有限公司 一种一锅煮法合成尼达尼布关键中间体的新方法
PT3722291T (pt) * 2015-12-24 2023-09-22 Respivert Ltd Compostos de indolinona e sua utilização no tratamento de doenças fibróticas
CZ2016104A3 (cs) 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
CA3017308A1 (en) 2016-03-08 2017-09-14 Respivert Limited Indole derivatives and their use as protein kinase inhibitors
US20190160054A1 (en) 2016-04-13 2019-05-30 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
EP3464240A1 (en) 2016-05-27 2019-04-10 Boehringer Ingelheim International GmbH Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
JP2019523225A (ja) 2016-06-01 2019-08-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブおよびピルフェニドンによる治療開始を決定するためのecmバイオマーカーの使用
KR102657707B1 (ko) 2016-06-02 2024-04-15 에이디에스 테라퓨틱스 엘엘씨 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법
CA3029851A1 (en) 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer
CN106748961A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的杂质化合物、制备方法、应用及其检测方法
CN106748960A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
CN110573161A (zh) 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 用于治疗肌营养不良的方法的尼达尼布
MX2020004173A (es) 2017-10-23 2020-08-03 Boehringer Ingelheim Int Nueva combinacion de agentes activos para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas (pf-ild).
CN111465594B (zh) 2017-11-17 2023-11-07 费米有限公司 已知作为制备尼达尼布中间体的2-吲哚满酮的合成
JP7061310B2 (ja) * 2018-04-05 2022-04-28 国立大学法人 大分大学 慢性脂肪性疾患の予防および治療用医薬
CN108358827A (zh) * 2018-05-07 2018-08-03 日照市普达医药科技有限公司 一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法
PE20211054A1 (es) * 2018-10-05 2021-06-07 Ichnos Sciences S A Compuestos de indolinona para uso como inhibidores de map4k1
US20230135671A1 (en) 2020-04-01 2023-05-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN112574094B (zh) * 2020-12-14 2022-07-01 成都大学 吲哚酮衍生物及其制药用途
EP4282874A1 (en) 2021-01-25 2023-11-29 Nibec Co., Ltd. Peptide for preventing and treating fibrosis
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN115703758B (zh) * 2021-08-12 2024-03-26 中国医学科学院药物研究所 一类用作激酶抑制剂的化合物及其制备方法和用途
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL96047C (US07585860-20090908-C00150.png) * 1956-06-08
CA2166722A1 (en) * 1994-05-06 1995-11-16 Manoj L. Maniar Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ATE243034T1 (de) * 1996-01-17 2003-07-15 Taiho Pharmaceutical Co Ltd Intimale verdickungsinhibitoren
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19824922A1 (de) 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
WO2001027081A1 (de) 2001-04-19
CN100455568C (zh) 2009-01-28
NO2015009I1 (no) 2015-03-30
PL207445B1 (pl) 2010-12-31
DK1224170T5 (en) 2018-01-22
AU1023301A (en) 2001-04-23
BRPI0014735B8 (pt) 2021-07-06
LU92681I9 (US07585860-20090908-C00150.png) 2019-01-03
PE20010671A1 (es) 2001-06-28
JP2003511441A (ja) 2003-03-25
BE2015C018I2 (US07585860-20090908-C00150.png) 2019-10-23
EA200200380A1 (ru) 2002-10-31
BRPI0014735A (pt) 2002-07-16
HK1052505B (zh) 2009-06-26
IL148756A (en) 2007-10-31
CA2387013C (en) 2009-12-29
EG25931A (en) 2012-10-24
CY1110067T1 (el) 2015-01-14
RS51013B (sr) 2010-10-31
IL148756A0 (en) 2002-09-12
DE50015711D1 (de) 2009-09-24
CZ20021410A3 (cs) 2002-07-17
DK1224170T3 (da) 2009-12-07
EP1224170B9 (de) 2017-11-22
PT1224170E (pt) 2009-10-01
MXPA02002799A (es) 2003-02-27
HRP20020306A2 (en) 2003-10-31
AU781939B2 (en) 2005-06-23
ATE439342T1 (de) 2009-08-15
CA2387013A1 (en) 2001-04-19
NO20021719D0 (no) 2002-04-11
EE05427B1 (et) 2011-06-15
MEP45408A (en) 2011-02-10
EE200200197A (et) 2003-06-16
EA006080B1 (ru) 2005-08-25
CY2015009I1 (el) 2016-12-14
BG65983B1 (bg) 2010-08-31
UA75054C2 (uk) 2006-03-15
PL355433A1 (en) 2004-04-19
BG106587A (bg) 2003-01-31
NL300725I2 (nl) 2017-07-13
BRPI0014735B1 (pt) 2012-07-10
MY127956A (en) 2007-01-31
HUP0204587A3 (en) 2004-07-28
YU26602A (sh) 2004-11-25
KR100835546B1 (ko) 2008-06-09
KR100857734B1 (ko) 2008-09-10
NO2015009I2 (US07585860-20090908-C00150.png) 2015-03-18
AR026036A1 (es) 2002-12-26
NZ518489A (en) 2005-05-27
NO20021719L (no) 2002-04-11
CZ301073B6 (cs) 2009-10-29
SA01210704B1 (ar) 2006-12-05
HUS1600022I1 (hu) 2017-02-28
KR20070095996A (ko) 2007-10-01
EP1224170A1 (de) 2002-07-24
HK1052505A1 (en) 2003-09-19
CN1391557A (zh) 2003-01-15
ES2331459T3 (es) 2010-01-05
JP2007302697A (ja) 2007-11-22
SI1224170T1 (sl) 2009-12-31
SK6462002A3 (en) 2002-08-06
NO2023033I1 (no) 2023-09-05
NO322746B1 (no) 2006-12-04
FR15C0024I1 (US07585860-20090908-C00150.png) 2015-04-17
JP4021664B2 (ja) 2007-12-12
CY2015009I2 (el) 2016-12-14
HUP0204587A2 (en) 2003-05-28
SK287312B6 (sk) 2010-06-07
HRP20020306B1 (en) 2010-09-30
CO5261488A1 (es) 2003-03-31
TWI268922B (en) 2006-12-21
LU92681I2 (fr) 2015-05-18
EP1224170B1 (de) 2009-08-12
FR15C0024I2 (fr) 2016-08-26
KR20020038949A (ko) 2002-05-24
EP2157081A1 (de) 2010-02-24

Similar Documents

Publication Publication Date Title
HU230416B1 (hu) 6-Helyzetben szubsztituált indolinonok, előállításuk és alkalmazásuk gyógyszerként
JP7307744B2 (ja) がん治療のための1-(ピペリジノカルボニルメチル)-2-オキソピペラジン誘導体
TWI363628B (en) Certain chemical entities, compositions, and methods
RU2167864C2 (ru) Производные индолин-2-она, способ их получения и содержащие их фармацевтические композиции
JP2004520324A (ja) カルバゾール誘導体およびニューロペプチドy5受容体リガンドとしてのそれらの使用
TW201718592A (zh) 新穎吡唑并[3,4-d]嘧啶化合物或其鹽
EP0764152A1 (en) Substituted indolylmethylene-oxindole analogues as tyrosine kinase inhibitors
TW200403060A (en) Inhibitors of tyrosine kinases
TW200911233A (en) Substituted indazole derivatives active as kinase inhibitors
TW200800899A (en) Novel compounds
JP2001518895A (ja) ソマトスタチン作働薬
US9611224B2 (en) Antiproliferative benzo [B] azepin-2-ones
TW200412957A (en) Therapeutic agents
TW201043603A (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
US10906884B2 (en) Benzodiazepine derivatives as CCK2/gastrin receptor antagonists
WO2002060392A2 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
KR101475168B1 (ko) 암 치료용 신규 n-하이드록시-벤즈아마이드
EA028604B1 (ru) Модуляторы рецептора cxcr7
US20100331355A1 (en) Substituted Quinolines for the Treatment of Cancer
AU2008200385B2 (en) Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
CA2481855A1 (en) Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
US20230234917A1 (en) Asparagine derivatives and methods of using same
EP3725777A1 (en) Benzo- and pyrido-pyrazoles as protein kinase inhibitors
TW200911757A (en) Crystalline forms of histone deacetylase inhibitors
US6358974B1 (en) Isoquinoline derivatives

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: NINTEDANIB, ITS TAUTOMERS AND THEIR SALTS, ESPECIALLY NINTEDANIB AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS, TYPICALLY NINTEDANIB ESYLATE; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141125

Spc suppl protection certif: S1600022

Filing date: 20160513

Expiry date: 20201009

FG4S Grant of supplementary protection certificate

Free format text: PRODUCT NAME: NINTEDANIB, ITS TAUTOMERS AND THEIR SALTS, ESPECIALLY NINTEDANIB AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS, TYPICALLY NINTEDANIB ESYLATE; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141125

Spc suppl protection certif: S1600022

Filing date: 20160513

Expiry date: 20201009

Extension date: 20251009